IRIS
SINAGRA, GIANFRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.060
AS - Asia 3.335
EU - Europa 2.634
SA - Sud America 674
Continente sconosciuto - Info sul continente non disponibili 107
AF - Africa 97
OC - Oceania 8
Totale 11.915
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.818
SG - Singapore 1.177
IT - Italia 1.007
CN - Cina 843
RU - Federazione Russa 645
BR - Brasile 501
VN - Vietnam 466
BD - Bangladesh 267
DE - Germania 208
HK - Hong Kong 195
GB - Regno Unito 148
CA - Canada 136
FR - Francia 110
SE - Svezia 87
IN - India 84
IE - Irlanda 76
AR - Argentina 70
FI - Finlandia 70
NL - Olanda 64
MX - Messico 56
PL - Polonia 56
TR - Turchia 47
ZA - Sudafrica 46
PK - Pakistan 41
ID - Indonesia 38
ES - Italia 36
UA - Ucraina 35
EC - Ecuador 31
JP - Giappone 31
IQ - Iraq 30
CO - Colombia 28
AT - Austria 23
LT - Lituania 20
IL - Israele 18
VE - Venezuela 18
SA - Arabia Saudita 17
UZ - Uzbekistan 15
AE - Emirati Arabi Uniti 12
BE - Belgio 12
JM - Giamaica 12
MA - Marocco 10
CL - Cile 9
EG - Egitto 9
KE - Kenya 9
CH - Svizzera 8
MY - Malesia 8
TN - Tunisia 8
JO - Giordania 7
OM - Oman 7
SI - Slovenia 6
CR - Costa Rica 5
KZ - Kazakistan 5
PE - Perù 5
PR - Porto Rico 5
PY - Paraguay 5
AU - Australia 4
AZ - Azerbaigian 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
NZ - Nuova Zelanda 4
PA - Panama 4
PH - Filippine 4
UY - Uruguay 4
AL - Albania 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
KR - Corea 3
NP - Nepal 3
PT - Portogallo 3
SN - Senegal 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BZ - Belize 2
CY - Cipro 2
GP - Guadalupe 2
GR - Grecia 2
HR - Croazia 2
MD - Moldavia 2
NO - Norvegia 2
RO - Romania 2
SV - El Salvador 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EE - Estonia 1
GD - Grenada 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
KY - Cayman, isole 1
LB - Libano 1
Totale 11.800
Salva come PNG Salva come JPEG
Città #
Dallas 1.831
Singapore 664
San Jose 448
Ashburn 438
Beijing 277
Council Bluffs 194
Hong Kong 187
Milan 180
Ho Chi Minh City 169
Los Angeles 129
New York 120
Rome 105
Moscow 104
Santa Clara 93
Hanoi 87
Dublin 76
Chandler 61
Munich 58
São Paulo 57
Orem 52
Lauterbourg 49
The Dalles 47
Warsaw 45
Hefei 44
Montreal 44
Buffalo 43
Phoenix 39
Helsinki 37
Frankfurt am Main 36
Johannesburg 34
Brooklyn 33
Boardman 31
Chennai 31
Columbus 31
San Mateo 30
Tokyo 29
Pisa 28
Bologna 27
Denver 27
London 27
Mexico City 27
Houston 25
Ottawa 25
Naples 24
Seattle 24
Amsterdam 23
Chicago 23
Atlanta 22
Beauharnois 22
Fairfield 22
Lappeenranta 22
Nuremberg 22
Poplar 22
Haiphong 21
Cambridge 20
Istanbul 19
Turin 19
Boston 18
Florence 18
Genoa 18
Da Nang 17
Portsmouth 17
Stockholm 16
West Jordan 16
Rio de Janeiro 15
San Francisco 15
Ankara 14
Brasília 14
Stevenage 14
Tashkent 14
Tel Aviv 14
Toronto 14
Kochi 13
Krefeld 13
Wilmington 13
Bari 12
Belo Horizonte 12
Biên Hòa 12
Padua 12
Querétaro 12
Guarulhos 11
Lahore 11
Lawrence 11
Manchester 11
Turku 11
Verona 11
Washington 11
Bad Bellingen 10
Brussels 10
Dong Ket 10
Figino 10
Kingston 10
Medellín 10
Ninh Bình 10
Paris 10
Porto Alegre 10
Brescia 9
Buenos Aires 9
Jeddah 9
Miami 9
Totale 6.960
Salva come PNG Salva come JPEG
Nome #
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 738
Impact of GFR Estimation Formulas on MECKI Score Performance and Prognostic Accuracy in Heart Failure: The MECKI-RENAL Study 487
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 451
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: Insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in Italian cardiac care units Registry 352
Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction 328
[Ten perspectives for research and innovation in cardiac amyloidosis] 299
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 297
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 278
Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test 264
Cardiac and neuromuscular features of patients with LMNA-related cardiomyopathy 261
[Transcatheter devices for chronic heart failure: state of the art] 256
Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension 247
Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry 246
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 242
Valvular heart disease in patients with cardiac amyloidosis 240
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 238
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 238
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study 234
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 232
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 228
Inferior Vena Cava Edge Tracking Echocardiography: A Promising Tool with Applications in Multiple Clinical Settings 228
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 226
Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score 222
Roles of periodic breathing and isocapnic buffering period during exercise in heart failure 222
Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study 218
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 217
Association between implantable defibrillator-detected sleep apnea and atrial fibrillation: The DASAP-HF study 215
The chronic heart failure evolutions: Different fates and routes 212
Heart failure patients with improved ejection fraction: Insights from the MECKI score database 212
Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group 201
Pressure-volume relationship by pharmacological stress cardiovascular magnetic resonance 199
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 199
Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set 189
Myocarditis and pericarditis during COVID-19 pandemic: a study of the Italian Society of Cardiology 188
Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension 185
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 179
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 174
Change in prevalence of ATTR variants in Italy: results from a national survey 172
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis 171
Cardiac amyloidosis: when to suspect and how to confirm 161
Global Right Heart Assessment with Speckle-Tracking Imaging Improves the Risk Prediction of a Validated Scoring System in Pulmonary Arterial Hypertension 157
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 145
Tafamidis in the Treatment of ATTR-related Cardiomyopathy 118
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy 118
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry 90
Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis 89
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis 86
Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: The MECKI-RENAL study 83
Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC) 79
Changes in CMR-derived ventricular strain, fibrosis progression and outcomes in hypertrophic cardiomyopathy 74
Current Standards and Perspectives in Proteomics for Cardiac Amyloidosis 68
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population 66
Analysis of Calcium Scores in Severe Aortic Stenosis Patients With and Without Cardiac Amyloidosis 66
Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: the MECKI-RENAL study 64
Analysis of Calcium Scores in Severe Aortic Stenosis Patients With and Without Cardiac Amyloidosis: The CAUSATIVE Study 59
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 56
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy 56
Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies 52
ECG/echo indexes in the diagnostic approach to amyloid cardiomyopathy: A head-to-head comparison from the AC-TIVE study 51
Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact 47
Electrocardiographic abnormalities in patients with cardiomyopathies 41
Late gadolinium enhancement dispersion for predicting malignant arrhythmic events in patient with non-ischaemic dilated cardiomyopathy 35
null 26
High Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis in Older Adults with Carpal Tunnel Syndrome, Heart Failure or Increased Left Ventricular Mass: The CAPTURE Study 22
Diagnostic Role of Wall Thickness Heterogeneity in Hypertrophic Cardiomyopathy and in Carriers of Sarcomeric Gene Mutations 21
Totale 11.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022155 0 25 2 19 0 6 19 25 10 28 7 14
2022/2023204 12 21 3 15 22 23 5 23 52 1 17 10
2023/2024332 10 7 39 23 5 16 13 27 43 33 33 83
2024/20251.825 31 81 137 52 112 90 243 397 160 70 265 187
2025/20268.750 311 944 1.798 876 686 503 715 488 709 585 594 541
2026/2027529 264 265 0 0 0 0 0 0 0 0 0 0
Totale 11.915